This inventor holds 2 USPTO granted patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2013-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2015
Title: Innovations by Toshihide Saito
Introduction
Toshihide Saito is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid dosage forms. With a total of 2 patents, his work focuses on improving the printability and disintegration of pharmaceutical preparations.
Latest Patents
Saito's latest patents include a method for the treatment of solid pharmaceutical preparation prior to printing. This invention aims to enhance the printability and abrasion resistance of prints on solid dosage forms. The method involves treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution before printing. Additionally, he has developed a method of producing solid preparations that disintegrate in the oral cavity. This method includes mixing fine subtilaes containing a medicinal ingredient with an additive containing δ-mannitol and tableting the mixture. The resulting solid preparation is designed to maintain its strength during transportation and packaging.
Career Highlights
Toshihide Saito is currently associated with Takeda Pharmaceutical Company Limited, a leading global pharmaceutical company. His work at Takeda has allowed him to focus on innovative solutions in drug formulation and delivery.
Collaborations
Saito has collaborated with notable colleagues such as Hiroshi Fukada and Shigehiro Higuchi. These collaborations have contributed to the advancement of pharmaceutical technologies and innovations.
Conclusion
Toshihide Saito's contributions to the pharmaceutical industry through his patents and collaborations highlight his commitment to innovation in drug formulation. His work continues to impact the field positively, paving the way for advancements in solid dosage forms.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
